Stefan Wietek Selected Research

Octagam

1/2018	Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies.
11/2016	Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials .

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Wietek Research Topics

Disease

3	Torticollis (Wryneck) 01/2021 - 01/2021
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 05/2018 - 11/2016
1	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2018
1	Guillain-Barre Syndrome 11/2016
1	Drug-Related Side Effects and Adverse Reactions 11/2016
1	Sudden Infant Death (SID) 11/2016
1	Autoimmune Diseases (Autoimmune Disease) 11/2016
1	Relapsing-Remitting Multiple Sclerosis 12/2014
1	Alzheimer Disease (Alzheimer's Disease) 03/2013
1	Stroke (Strokes) 03/2013

Drug/Important Bio-Agent (IBA)

3	abobotulinumtoxinA FDA Link 01/2021 - 01/2021
3	Intravenous Immunoglobulins (IVIG)FDA Link 05/2018 - 03/2013
2	OctagamIBA 01/2018 - 11/2016
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2021
1	Inosine Triphosphate (ITP)IBA 05/2018
1	Biomarkers (Surrogate Marker)IBA 03/2013

Therapy/Procedure

2	Injections 01/2021 - 01/2021